Intuitive Surgical, Inc. $ISRG Shares Bought by Capital Analysts LLC

Capital Analysts LLC lifted its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 324.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,354 shares of the medical equipment provider’s stock after purchasing an additional 1,800 shares during the quarter. Capital Analysts LLC’s holdings in Intuitive Surgical were worth $936,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the company. Main Street Group LTD purchased a new stake in Intuitive Surgical during the first quarter worth $30,000. Compass Financial Management LLC acquired a new position in shares of Intuitive Surgical in the second quarter worth about $30,000. Vermillion Wealth Management Inc. raised its position in shares of Intuitive Surgical by 58.1% in the first quarter. Vermillion Wealth Management Inc. now owns 68 shares of the medical equipment provider’s stock worth $31,000 after acquiring an additional 25 shares during the period. Motiv8 Investments LLC purchased a new stake in shares of Intuitive Surgical during the 4th quarter worth about $34,000. Finally, Evergreen Advisors LLC purchased a new stake in shares of Intuitive Surgical during the 1st quarter worth about $35,000. 83.64% of the stock is owned by hedge funds and other institutional investors.

Intuitive Surgical Price Performance

Shares of NASDAQ:ISRG opened at $360.46 on Friday. Intuitive Surgical, Inc. has a 1 year low of $328.57 and a 1 year high of $603.88. The firm has a market capitalization of $127.34 billion, a PE ratio of 41.29, a P/E/G ratio of 2.67 and a beta of 1.47. The business’s 50 day moving average price is $377.41 and its 200-day moving average price is $424.21.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings data on Thursday, July 16th. The medical equipment provider reported $2.80 EPS for the quarter, beating the consensus estimate of $2.48 by $0.32. Intuitive Surgical had a return on equity of 16.91% and a net margin of 28.45%.The firm had revenue of $2.89 billion during the quarter, compared to the consensus estimate of $2.83 billion. The firm’s revenue was up 18.4% compared to the same quarter last year. During the same period in the prior year, the company earned $1.81 EPS. As a group, analysts expect that Intuitive Surgical, Inc. will post 8.85 earnings per share for the current year.

Intuitive Surgical News Summary

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: A meta-analysis found that da Vinci robotic-assisted surgery produced statistically significant improvements across 13 common benign conditions, including shorter hospital stays and faster returns to work versus laparoscopic and open surgery. The results reinforce the clinical value of Intuitive’s platform and could support further hospital adoption. Intuitive reports positive meta-analysis data
• Positive Sentiment: BTIG reiterated its Buy rating and set a $469 price target, signaling considerable potential upside. Broader analyst coverage remains favorable, with the stock described as trading at its cheapest valuation in roughly a decade. Recent earnings also showed strong execution, including 18.4% year-over-year revenue growth and an earnings beat. BTIG reiterates Buy rating
• Neutral Sentiment: Intuitive Surgical presented at the Wells Fargo Healthcare Conference. Investors are focused on management’s commentary regarding procedure trends, guidance, competition, costs and the long-term opportunity for robotic surgery. Wells Fargo Healthcare Conference transcript
• Neutral Sentiment: Reported short-interest data showed zero shares and a zero-day short-interest ratio, suggesting no measurable short positioning in the supplied data; however, the figures appear anomalous and should not be treated as a meaningful trading signal.
• Negative Sentiment: EVP Mark Brosius disclosed sales totaling 69 shares at approximately $350.20 and $361.23 under a pre-arranged Rule 10b5-1 plan. The transactions are small relative to his remaining holdings and are not necessarily bearish, but continued insider selling provides little additional support for the shares. Intuitive Surgical EVP stock sale
• Negative Sentiment: Investors remain concerned about slower U.S. procedure growth, rising costs, competitive pressure and the possibility that GLP-1 drugs could affect procedure volumes. Options markets also indicate that substantial volatility may persist after the stock’s steep decline from its 52-week high. ISRG volatility outlook

Insider Buying and Selling at Intuitive Surgical

In other news, EVP Mark Brosius sold 77 shares of the company’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $375.57, for a total transaction of $28,918.89. Following the completion of the sale, the executive vice president owned 881 shares of the company’s stock, valued at $330,877.17. This represents a 8.04% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Gary Guthart sold 10,000 shares of the stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $400.00, for a total transaction of $4,000,000.00. Following the completion of the sale, the director owned 1,245,679 shares of the company’s stock, valued at $498,271,600. This trade represents a 0.80% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 11,256 shares of company stock worth $4,475,079. Company insiders own 0.60% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently weighed in on ISRG shares. BNP Paribas Exane upgraded Intuitive Surgical to an “outperform” rating in a research note on Tuesday, July 28th. Truist Financial lowered their price target on Intuitive Surgical from $580.00 to $510.00 and set a “buy” rating on the stock in a research report on Thursday, July 16th. Citigroup dropped their price objective on Intuitive Surgical from $590.00 to $500.00 and set a “buy” rating on the stock in a report on Friday, July 17th. UBS Group initiated coverage on Intuitive Surgical in a research report on Tuesday, July 28th. They set a “neutral” rating and a $500.00 target price on the stock. Finally, Robert W. Baird decreased their price objective on shares of Intuitive Surgical from $525.00 to $500.00 and set an “outperform” rating on the stock in a report on Friday, July 17th. Twenty-two equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Intuitive Surgical has an average rating of “Moderate Buy” and an average price target of $508.68.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc is a medical technology company that develops and manufactures robotic-assisted surgical systems and related products. Its technology is designed to support surgeons during minimally invasive procedures by providing enhanced visualization, instrument control and dexterity.

The company’s principal product is the da Vinci Surgical System, which is used across a range of specialties, including general surgery, urology, gynecology, cardiothoracic surgery and other procedures.